氯胺酮对抑郁症药物研发的影响。
The influence of ketamine on drug discovery in depression.
机构信息
Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, USA.
Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, USA.
出版信息
Drug Discov Today. 2019 Oct;24(10):2033-2043. doi: 10.1016/j.drudis.2019.07.007. Epub 2019 Aug 2.
Abstract
Recent research demonstrating that the glutamatergic modulator ketamine has rapid, robust, and sustained antidepressant effects has been a turning point in drug discovery for depression. The recent FDA approval of esketamine for adults with treatment-resistant major depressive disorder (MDD) has further underscored the relevance of this agent in spurring investigation into novel and mechanistically distinct agents for use in depression. Over the past two decades, ketamine research has ushered in a new wave of studies seeking to not only identify its mechanism of action but also to examine the antidepressant potential of novel or repurposed agents. This article reviews the approaches that have proven particularly fruitful for the field of neuropsychiatry.
摘要
最近的研究表明，谷氨酸调节剂氯胺酮具有快速、强大和持久的抗抑郁作用，这是抑郁症药物发现的一个转折点。最近 FDA 批准氯胺酮用于治疗难治性重度抑郁症（MDD）的成年人，进一步强调了该药物在推动对新型、机制不同的抗抑郁药物的研究中的相关性。在过去的二十年中，氯胺酮研究迎来了一波新的研究浪潮，不仅旨在确定其作用机制，还旨在研究新型或重新定位药物的抗抑郁潜力。本文综述了对神经精神病学领域特别有成效的方法。
相似文献
1
The influence of ketamine on drug discovery in depression.氯胺酮对抑郁症药物研发的影响。
Drug Discov Today. 2019 Oct;24(10):2033-2043. doi: 10.1016/j.drudis.2019.07.007. Epub 2019 Aug 2.
2
Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.氯胺酮治疗抑郁症：临床治疗进展、快速抗抑郁作用机制以及与血清素能致幻剂的对比
Curr Top Behav Neurosci. 2022;56:141-167. doi: 10.1007/7854_2022_313.
3
Ketamine: Mechanisms and Relevance to Treatment of Depression.氯胺酮：作用机制与抗抑郁治疗的相关性。
Annu Rev Med. 2024 Jan 29;75:129-143. doi: 10.1146/annurev-med-051322-120608. Epub 2023 Sep 20.
4
Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.依他佐辛和裸盖菇素——两种治疗抑郁症致幻药物的比较：系统评价。
Int J Mol Sci. 2022 Sep 28;23(19):11450. doi: 10.3390/ijms231911450.
5
The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?谷氨酸能系统在治疗抵抗性抑郁症中的作用和氯胺酮与艾司氯胺酮的比较疗效：炎症的作用？
Adv Exp Med Biol. 2023;1411:487-512. doi: 10.1007/978-981-19-7376-5_21.
6
Ketamine for Major Depressive Disorder.氯胺酮治疗重度抑郁症。
Curr Top Behav Neurosci. 2024;66:131-147. doi: 10.1007/7854_2023_453.
7
The rapid-onset antidepressant effect of ketamine: More surprises?氯胺酮的快速起效抗抑郁作用：还有更多惊喜吗？
J Clin Pharm Ther. 2018 Apr;43(2):308-311. doi: 10.1111/jcpt.12656. Epub 2017 Nov 26.
8
Esketamine for treatment resistant depression: a trick of smoke and mirrors?用于治疗抵抗性抑郁症的 Esketamine：烟雾与镜子的把戏？
Epidemiol Psychiatr Sci. 2019 Dec 16;29:e79. doi: 10.1017/S2045796019000751.
9
Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.AMPA 受体参与氯胺酮在抑郁动物模型中快速和持续的抗抑郁样作用。
Behav Brain Res. 2011 Oct 10;224(1):107-11. doi: 10.1016/j.bbr.2011.05.035. Epub 2011 Jun 6.
10
Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).抗抑郁治疗抵抗性抑郁症（TRD）中使用致幻剂的疗效、安全性和耐受性。
Adv Exp Med Biol. 2024;1456:49-66. doi: 10.1007/978-981-97-4402-2_3.
引用本文的文献
1
Glutamatergic Modulators for Major Depression from Theory to Clinical Use.用于重度抑郁症的谷氨酸能调节剂：从理论到临床应用。
CNS Drugs. 2024 Nov;38(11):869-890. doi: 10.1007/s40263-024-01114-y. Epub 2024 Aug 16.
2
Modulation of habenular and nucleus accumbens functional connectivity by ketamine in major depression.在重度抑郁症中，氯胺酮对缰核和伏隔核功能连接的调制作用。
Brain Behav. 2024 Jun;14(6):e3511. doi: 10.1002/brb3.3511.
3
Alterations in Astrocytic Regulation of Excitation and Inhibition by Stress Exposure and in Severe Psychopathology.应激暴露和严重精神病理学中星形胶质细胞对兴奋和抑制的调节改变。
J Neurosci. 2022 Sep 7;42(36):6823-6834. doi: 10.1523/JNEUROSCI.2410-21.2022.
4
Microdosing ketamine in Drosophila does not block serotonin reuptake, but causes complex behavioral changes mediated by glutamate and serotonin receptors.在果蝇中微剂量使用氯胺酮不会阻断5-羟色胺再摄取，但会引起由谷氨酸和5-羟色胺受体介导的复杂行为变化。
J Neurochem. 2024 Jun;168(6):1097-1112. doi: 10.1111/jnc.16070. Epub 2024 Feb 7.
5
Electrochemical and biosensor techniques to monitor neurotransmitter changes with depression.电化学和生物传感器技术监测抑郁症相关神经递质变化。
Anal Bioanal Chem. 2024 Apr;416(9):2301-2318. doi: 10.1007/s00216-024-05136-9. Epub 2024 Jan 30.
6
Microdosing ketamine in does not inhibit SERT like SSRIs, but causes behavioral changes mediated by glutamate and serotonin receptors.小剂量氯胺酮不会像选择性5-羟色胺再摄取抑制剂（SSRIs）那样抑制5-羟色胺转运蛋白（SERT），而是会引起由谷氨酸和血清素受体介导的行为变化。
bioRxiv. 2023 Nov 8:2023.11.07.566121. doi: 10.1101/2023.11.07.566121.
7
Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects.氯胺酮作为重度抑郁症和创伤后应激障碍的治疗药物：潜在的药用和有害影响。
Ibrain. 2023 Feb 20;9(1):90-101. doi: 10.1002/ibra.12094. eCollection 2023 Spring.
8
Inflammation in the pathogenesis of depression: a disorder of neuroimmune origin.炎症在抑郁症发病机制中的作用：一种神经免疫源性疾病。
Neuronal Signal. 2023 Jul 13;7(2):NS20220054. doi: 10.1042/NS20220054. eCollection 2023 Jul.
9
Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine.神经影像学衍生的氯胺酮抗抑郁作用生物标志物。
Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Apr;8(4):361-386. doi: 10.1016/j.bpsc.2022.11.005. Epub 2022 Nov 26.
10
Unraveling the Mysteries of Mental Illness With Psilocybin.用裸盖菇素揭开精神疾病的奥秘。
Cureus. 2022 May 27;14(5):e25414. doi: 10.7759/cureus.25414. eCollection 2022 May.
本文引用的文献
1
Do antidepressants restore lost synapses?抗抑郁药能恢复失去的突触吗？
Science. 2019 Apr 12;364(6436):129-130. doi: 10.1126/science.aax0719.
2
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation.抗抑郁药诱导的脊柱形成持续挽救前额叶回路功能障碍。
Science. 2019 Apr 12;364(6436). doi: 10.1126/science.aat8078.
3
()-hydroxynorketamine exerts mGlu receptor-dependent antidepressant actions.()-羟基去甲氯胺通过 mGlu 受体发挥抗抑郁作用。
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6441-6450. doi: 10.1073/pnas.1819540116. Epub 2019 Mar 13.
4
State of the art opioid-sparing strategies for post-operative pain in adult surgical patients.成人手术患者术后疼痛的最先进阿片类药物节约策略。
Expert Opin Pharmacother. 2019 Jun;20(8):949-961. doi: 10.1080/14656566.2019.1583743. Epub 2019 Feb 27.
5
Antidepressant-relevant concentrations of the ketamine metabolite (2,6)-hydroxynorketamine do not block NMDA receptor function.抗抑郁相关浓度的氯胺酮代谢产物 (2,6)-羟基去甲氯胺酮不会阻断 NMDA 受体功能。
Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169. doi: 10.1073/pnas.1816071116. Epub 2019 Feb 22.
6
Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.产后抑郁症的药物治疗：现有方法和新药研发。
CNS Drugs. 2019 Mar;33(3):265-282. doi: 10.1007/s40263-019-00605-7.
7
A report of affective switching associated with ketamine: The case of ketamine-induced mania is not closed.一篇关于与氯胺酮相关的情感转换的报告：氯胺酮诱发躁狂症的案例尚无定论。
Bipolar Disord. 2019 Mar;21(2):176-178. doi: 10.1111/bdi.12728. Epub 2019 Feb 1.
8
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.新一代抗抑郁药：基于谷氨酸/GABA 神经递质系统的新型快速作用治疗情绪障碍药物研发管线的最新进展。
Drug Discov Today. 2019 Feb;24(2):606-615. doi: 10.1016/j.drudis.2018.11.007. Epub 2018 Nov 14.
9
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.谷氨酸能神经传递：开发新型快速作用抗抑郁治疗方法的途径。
Int J Neuropsychopharmacol. 2019 Feb 1;22(2):119-135. doi: 10.1093/ijnp/pyy094.
10
Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.丁丙诺啡/纳洛酮组合对治疗重度抑郁症的阿片系统调节：两项随机对照研究。
Mol Psychiatry. 2020 Jul;25(7):1580-1591. doi: 10.1038/s41380-018-0284-1. Epub 2018 Oct 29.
Zotero 插件